![](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/07/cta2-shutterstock_1669658914.jpg)
Eluminex doses first patient in Phase I LOTUS trial for DME treatment
Chinese biotechnology company Eluminex Biosciences has dosed the first patient with its trispecific fusion antibody, EB-105, in the Phase I LOTUS trial for the treatment of diabetic macular oedema (DME). The first-in-human, open-label trial is being …